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A novel small-molecule inhibitor 
of influenza A virus acts by 
suppressing PA endonuclease 
activity of the viral polymerase
Shuofeng Yuan1, Hin Chu1, Kailash Singh2, Hanjun Zhao1, Ke Zhang1, Richard Y. T. Kao1, 
Billy K. C. Chow2, Jie Zhou1 & Bo-Jian Zheng1
The RNA-dependent RNA polymerase of influenza A virus comprises conserved and independently-
folded subdomains with defined functionalities. The N-terminal domain of the PA subunit (PAN) harbors 
the endonuclease function so that it can serve as a desired target for drug discovery. To identify a 
class of anti-influenza inhibitors that impedes PAN endonuclease activity, a screening approach that 
integrated the fluorescence resonance energy transfer based endonuclease inhibitory assay with the 
DNA gel-based endonuclease inhibitory assay was conducted, followed by the evaluation of antiviral 
efficacies and potential cytotoxicity of the primary hits in vitro and in vivo. A small-molecule compound 
ANA-0 was identified as a potent inhibitor against the replication of multiple subtypes of influenza A 
virus, including H1N1, H3N2, H5N1, H7N7, H7N9 and H9N2, in cell cultures. Combinational treatment 
of zanamivir and ANA-0 exerted synergistic anti-influenza effect in vitro. Intranasal administration of 
ANA-0 protected mice from lethal challenge and reduced lung viral loads in H1N1 virus infected BALB/c 
mice. In summary, ANA-0 shows potential to be developed to novel anti-influenza agents.
The continuous zoonotic circulation and re-assortment potential of influenza A viruses in nature have been pos-
ing an enormous public health threat to humans1–3. Due to the limitations of vaccines, which are about 0.5–1 
year lagged because of the rapid mutations of the virus genes, antiviral drugs represent an important approach 
to combat human influenza diseases, particularly in the early stage of influenza outbreaks and pandemics4. Two 
classes of antiviral drugs, targeting the matrix protein 2 (M2) and the neuraminidase (NA) protein of influenza 
virus, have been approved for clinical treatment. However, the prevalence of drug-resistant strains, e.g. in sea-
sonal H3N2, pandemic H1N1, avian influenza H5N1 and H7N9, has undermined their clinical benefits to certain 
extent5–7. In this regard, new antivirals with cross-protection are highly desired. Biological and structural investi-
gations of the functional domains of these subunits have broadened the target reservoir for drug screening. With 
the wealth of knowledge from these studies, identification of small-molecule inhibitors that specifically disrupt 
the polymerase assembly or abrogate polymerase activity has emerged as an innovative and promising approach8. 
Importantly, the domains that are responsible for the above-mentioned functions are fairly conserved9. Therefore, 
drugs with cross-subtype antiviral effects are likely to be discovered.
The RNA-dependent RNA polymerase (RdRp) of influenza A virus, which consists of the PB1, PB2 and PA 
subunits, serves as the hub for viral transcription and replication10. The viral gene transcription is primed by 
short-capped oligonucleotides that are cleaved from host cell pre-mRNAs by PA endonuclease activity, a process 
known as ‘cap-snatching’11. The N-terminal domain of PA subunit (PAN) has been confirmed to accommodate the 
endonuclease activity residues, which is highly conserved among subtypes of influenza A virus and is able to fold 
functionally in vitro12,13. Importantly, substitutions in this functional domain, particularly the catalytic residues, 
were expected to considerably reduce the viral fitness14,15. In this regard, the emergence of resistant virus mutants 
induced by PAN antivirals may be significantly delayed.
Amino acid residues in the PAN region play critical roles in endonuclease activity, protein stability and vRNA 
promoter binding13. One recent study revealed that PAN-derived peptides effectively inhibited ribonucleoprotein 
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(RNP) activity via suppression of RNP expression, suggesting that this region itself might be potential influ-
enza virus inhibitors16. Determination of the PAN crystal structure12,13 has paved the path for the develop-
ment of endonuclease inhibitors, including 2,4-dioxobutanoic acid derivatives17–20, flutimide derivatives17,18,21, 
3-hydroxyquinolin-2(1H)-ones and 3-hydroxypyridin-2(1H)-ones22,23, as well as tetramic acid derivatives24. 
These endonuclease inhibitors were screened by computational modeling25–27 or identified through the measure-
ment of nucleic acid hydrolysis28,29 or cap-snatching activity30. Recently, a fluorescence polarization assay has been 
established for screening small-molecule binders of PAN, through which a group of endonuclease inhibitors were 
identified31. However, PAN-targeted inhibitor that possesses promising clinical potential is rare. In an attempt 
to facilitate the discovery of PA endonuclease inhibitors, we performed a screening that integrated fluorescence 
resonance energy transfer (FRET) based endonuclease inhibitory assay29 with DNA gel-based endonuclease 
inhibitory test12. FRET relies on the distance-dependent energy transfer between two labeled molecules32, it has 
been successfully applied in high-throughput screening (HTS) to identify inhibitors of numerous targets33,34. In 
this report, we described the optimization, validation and application of the FRET-based endonuclease assay for 
screening of a chemical library35 with 950 small-molecule compounds. A number of influenza A inhibitors were 
identified. We then proceeded to conduct various experiments to investigate the antiviral mechanism. Notably, 
an inhibitor(5Z)-2-[2-(2-oxoindol-3-yl)hydrazinyl]-5-(2-oxo-1H-indol-3-ylidene)-1,3-thiazol-4-one, designated 
ANA-0, exhibited potent and cross-subtype antiviral effects with high selectivity index.
Results
Establishment of FRET-based endonuclease inhibitory assay. The FRET-based endonuclease inhib-
itory assay was developed for screening of PA endonuclease inhibitors. To detect the endonuclease activity of PAN, 
we first demonstrated a dose-dependent increase of fluorescence intensity over time upon PAN addition to the 
dual-labeled probe (Fig. 1a). The fluorescence signals reached a plateau at 2 h post-reaction. Compared with the 
baseline, a maximal of 4-fold signal increase could be detected with the input of 75 ng/μl of PAN. In contrast, the 
mock purified enzyme protein (i.e. pET-blank protein), regardless of the amounts of addition (75 and 50 ng/μl), 
exhibited similar readouts as that of the background control (i.e. substrate only). The result suggested that the 
purified PAN indeed maintained the endonuclease activity. To validate the specificity, fluorescence signals were 
recorded in the presence or absence of a known PA endonuclease inhibitor DPBA36. At the fixed concentration of 
75 ng/μl of PAN, a dose-dependent inhibition was detected, in which higher concentrations of DPBA resulted in 
Figure 1. Detection of PAN endonuclease activity by FRET-based assay. The fluorescence intensity of each 
reaction was recorded at indicated time-points. (a) PAN of depicted concentrations were reacted with 200 nM of 
the dual-labeled probe, while pET-blank protein and substrate only were included as a mock-purified enzyme 
control and a background control, respectively. (b) Indicated concentrations of DPBA were incubated with a 
mixture of 75 ng/μl PAN and 200 nM probe. Fluorescence intensities were recorded and results are represented. 
Reactions of each condition were done in triplicate. (c) Fitting of DPBA dose-response curve to yield IC50 by 
nonlinear regression model. Results are shown as the mean values ± SD.
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lower fluorescence intensities (Fig. 1b). The result suggested that the PAN endonuclease activity was specifically 
inhibited by DPBA. The inhibitory constant (Ki) and 50% inhibitory concentration (IC50) of DPBA in this assay 
were estimated as 12.8 μM and 13.2 μM (Fig. 1c), respectively. These results were in the range of those reported 
previously by others12,20,29 and supporting that a sensitive and specific FRET-based endonuclease inhibitory assay 
was established for the effective screening of endonuclease inhibitors.
Identification of antiviral compounds. As shown in Fig. 2a, compounds in the library were first screened 
at a fixed concentration of 10 μg/ml (25~50 μM) using the established FRET-based endonuclease inhibitory assay. 
A total of 77 compounds displayed the decreased fluorescence intensities that > 50%. We then performed the 
DNA-gel based endonuclease inhibitory analyses to exclude false-positive results that might be produced by 
fluorescence interference from the compound itself (Fig. 2b). It was demonstrated that the PAN was endonucle-
ase active as the M13mp18 substrate was largely diminished under the PAN digestion (lane N), in contrast, the 
substrate remained intact in both the substrate and the buffer controls (lane Z and B). As a result, 27 compounds 
were defined as ‘active’ by showing stronger endonuclease inhibitory effect than that of 10 μM DPBA (lane P). 
Next, a dose-response analysis was performed to identify the compounds that could consistently suppress the 
PAN endonuclease activity. In this experiment, a total of 8 compounds were selected due to their endonucle-
ase inhibitory activities in a concentration-dependent manner. Subsequently, a cell-based secondary screening 
was applied to search inhibitors with antiviral activities. Four compounds, namely PA-24, PA-30, PA-35 and 
PA-48 (Fig. 3a), were identified to reduce the plaque number in a dose-dependent manner and were regarded 
as antiviral-effective compounds. The selectivity index of individual compound, defined by the ratio of 50% cel-
lular cytotoxicity concentration (CC50) over IC50, was determined to prioritize these 4 compounds. The results 
showed that PA-30 possessed the highest selectivity index (> 200, Fig. 3b). Based on the structural properties 
of compounds PA-24, PA-30, PA-35 and PA-48, structural similar analogs with apparently good water solubility 
(logSw > − 4.75) and low molecular weight (MW < 425)37 were purchased from commercial sources. A total of 14 
analogs were obtained, whose selectivity index was scored individually. Compound ANA-0 (Fig. 3a), an analog of 
PA-30, exhibited the best selectivity index that > 500 and was chosen for further evaluation.
We then conducted a multi-cycle virus growth assay to evaluate the antiviral efficacies of PA-30 and ANA-0. 
Both compounds displayed dramatic anti-H1N1 effects with 2–3 log reduction in supernatant viral titer (sup-
plementary Fig. S2), while ANA-0 showed higher selectivity index than that of PA-30 (Fig. 3b). Thus, we further 
evaluated the cross-subtype antiviral effect of PA-30 and ANA-0 in vitro.
Figure 2. Identification of compounds by their inhibitory activity of endonuclease. (a) Schematic diagram 
of FRET-based assay and attrition rates of compounds from primary screening, gel-based endonuclease 
inhibitory assay and dose-response analysis. (b) Screening of compounds with gel-based endonuclease 
inhibitory assay. The single-strand circular DNA M13mp18 was used as the substrate. The substrate control 
(lane Z), buffer control (lane B) and no-compound control (lane N) were included as negative controls. 
DPBA (10 μM) was taken as a positive control (lane P) and was carried out every 10 candidate compounds 
for reference comparison. In each reaction, 10 μM of individual compound was mixed with 1 μM PAN and 
subsequently incubated with 0.2 μg M13mp18 substrate in 10 μl volume. The images were based on DNA 
agarose gels and ethidium bromide staining.
www.nature.com/scientificreports/
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ANA-0 provided cross-subtype protection against influenza A virus infections in vitro. Since 
the sequence of PAN is highly conserved among viral strains (supplementary Fig. S1), we speculated that ANA-0 
and PA-30, which were considerably effective against H1N1 virus infection (supplementary Fig. S2), might 
be capable to provide cross-protection against the infections of other subtypes of influenza virus. To this end, 
cross-subtype antiviral effects of both agents were tested against infections of H3N2, H5N1, H7N7, H7N9 and 
H9N2 viruses in cell cultures. The results showed that both ANA-0 and PA-30 inhibited viral replication of all 
tested subtypes of influenza virus in a dose-dependent manner (Fig. 4). At 20 μM, ANA-0 suppressed the virus 
replication of all tested subtypes by more than 3 logs, whereas different subtypes of the virus exhibited variable 
sensitivities to ANA-0 (Fig. 4a). For example, ANA-0 showed superior antiviral effect against H1N1 and H9N2 
virus infection with IC50s lower than 1 μM. In contrast, it required 5-fold higher concentrations to achieve the 
similar level of inhibition against H3N2 and H7N9 viruses’ infections, while IC50s of ANA-0 against infections 
of H5N1 and H7N7 viruses were around 2.5 μM. PA-30 exhibited similar pattern of antiviral activity with that of 
ANA-0 (Fig. 4b).
ANA-0 inhibited virus growth in vivo. To assess the in vivo antiviral effect of ANA-0, mice challenged 
with LD80 of mouse-adapted H1N1 virus were treated with ANA-0 or PA-30 or zanamivir or PBS. As shown in 
Fig. 5a, all mice that received intranasal treatment with 2 mg/kg/day ANA-0 or 2 mg/kg/day zanamivir survived 
(p = 0.0003), while 2 mg/kg/day PA-30-treated group showed 80% survival rate (p = 0.0049); in contrast, 80% 
mice died in PBS-treated group. Four mice were euthanized from each group on the 4th day after infection and 
their lungs were tested for virus titer by plaque assay and RT-qPCR. The results showed that ANA-0-treated group 
exhibited significant reduction of viral loads in the lung tissues as compared with the control group (p = 0.0013 by 
plaque assay and p = 0.0006 by RT-qPCR), while PA-30-treated group inhibited virus growth by more than 1 log 
(p = 0.0032 by plaque assay and p = 0.0008 by RT-qPCR). Histopathologic examination further showed that the 
alveolar damage and interstitial inflammatory infiltration in lung tissues of the mice treated by ANA-0 or PA-30 
were much ameliorated than that of those treated by PBS (Fig. 5c). The results demonstrated that ANA-0 could 
effectively inhibit the influenza virus propagation in vivo.
ANA-0 inhibited the viral transcription. To verify the antiviral mechanism of ANA-0, we first deter-
mined which phase of virus life cycle was interrupted by ANA-0. As shown in Fig. 6a, ANA-0 did not exert antivi-
ral efficacy when it was added during virus absorption (i.e. -1 h p.i.) and subsequently removed after virus entry. 
A significant decrease of viral RNAs (vRNAs), both intracellular (p = 0.0074) and in the supernatant (p = 0.0183), 
were detected when ANA-0 were maintained in the culture medium after virus entry (i.e. 1 h p.i.). In contrast, 
addition of zanamivir reduced the vRNA in the supernatant but not inside the cells (Fig. 6a). The results sup-
ported that ANA-0 interfered the virus life cycle at stages after virus internalization but prior to budding. We 
Figure 3. Chemical structures and selectivity indexes of antiviral compounds. (a) Chemical structures of 
antiviral compounds PA-24, PA-30, PA-35, PA-48 and the PA-30′ s analog ANA-0 are shown. (b) Selectivity 
index of each compound was calculated by CC50/IC50. For CC50 determination, the highest concentrations of the 
compounds PA-30 and ANA-0 cannot be determined in MTT assay due to solubility limitations.
www.nature.com/scientificreports/
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further investigated which step of viral replication was interfered. As shown in Fig. 6b, ANA-0 treatment reduced 
the viral mRNA production at either 3 or 6 h post-infection, suggesting that ANA-0 inhibited the viral transcrip-
tion. Since the primary viral transcription occurs before viral genome replication38, the treatment of ANA-0 
also resulted in subsequent decrease of vRNAs in cell lysates (p = 0.0412 for 3 h p.i. and p = 0.0067 for 6 h p.i. 
(Fig. 6b)). The results indicated that ANA-0 disrupted the transcriptional stage of virus life cycle so that inhibited 
viral replication. We then conducted a mini-replicon assay to investigate the inhibitory efficacy of ANA-0 on 
the influenza polymerase activity. As shown in Fig. 6c, a dose-dependent suppression of luciferase activity was 
observed, suggesting that the viral polymerase function was impaired in the presence of ANA-0.
Synergistic antiviral effect of ANA-0 and zanamivir in vitro. Since antiviral mechanism of ANA-0 
was distinct from the commonly prescribed influenza NA inhibitor zanamivir, we further investigated the poten-
tial synergistic antiviral effects between two agents in vitro. Fractional inhibitory concentration index (FICI) is 
one of the popular methodologies for evaluating the nature of drug-drug combination39,40. The FICI is based 
on the Loewe additive zero-interaction theory41, assuming that a self-drug combination will always be additive, 
with an FICI of 1; while an FICI lower or higher than 1 indicates synergy or antagonism, respectively, because 
less or more drug would be required in order to produce the same effect as the drugs alone. In this study, five sets 
of combinations were conducted and FICI of each was determined. As shown in Table 1, all tested combinations 
resulted in FICI that < 0.5, which suggested the strong synergism existed between ANA-0 and zanamivir. Among 
the five, binary usage of 0.8 μM ANA-0 and 0.05 μM zanamivir, i.e. combination ratio (IC50) 1:1, exerted the best 
synergistic efficacy (FICI = 0.24) against virus infection (Table 1).
ANA-0 was predicted to interact with the PA endonuclease pocket. Molecular docking was per-
formed to predict the essential amino acid residues in PAN that were responsible for the interaction with ANA-0 
or its parent compound PA-30 (Fig. 7). A parallel study using DPBA as a natural ligand was included. The pre-
diction revealed that ANA-0 bound to the catalytic residues Lys-134, the metal binding residues His-41, Glu-80, 
Asp-108, Glu-119 and two strictly conserved residues Arg-84 and Lys-137 of PAN structure (Fig. 7a); while PA-30 
interacted with the residues of Ala-20, Leu-42, Glu-80, Gly-81 and Leu-106 (Fig. 7b). The predictions suggested 
that ANA-0 and PA-30 were likely to bind to the PAN endonuclease cavity. In addition, the Kd values of ANA-0 
Figure 4. In vitro antiviral activity of ANA-0 and PA-30. Antiviral activities of ANA-0 (a) and PA-30 (b) were 
determined by plaque assays. MDCK cells were infected with different strains of virus as shown, at MOI of 0.002. 
One hour after virus inoculation, the inoculum was removed and replaced by fresh MEM medium containing 
serial-diluted compound. The cell-free supernatants were collected at 24 h post-infection and titrated by standard 
plaque assay. The experiments were carried out in triplicate and repeated twice. Data are represented as mean 
values + SD. Differences between various concentrations treatments were compared and analyzed using a one-
way ANOVA. *indicates p < 0.05 as compared to mock-treated group.
www.nature.com/scientificreports/
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and PA-30 to PAN were experimentally determined to be 1.1 μM and 1.3 μM, respectively (Fig. 7c). In comparison 
with the reported Kd of DPBA17, i.e. 4.5 μM, the result suggested that the identified compounds bound tighter to 
the PAN. Since the predicted interaction amino acids of ANA-0 were key for the PAN endonuclease activity, the 
results supported that ANA-0 was an endonuclease inhibitor by binding to the enzyme activity sites.
Discussion
In this study, we performed a systematic screening in a chemical library and identified a novel small-molecule 
compound with broad-spectrum antiviral activities against influenza A viruses. To establish the screening 
approach, we initially expressed the N-terminal domain of PA subunit that retained the endonuclease activity 
(Fig. 1a). Based on the rationale that cleavage of 5′ -fluorophore and 3′ -quencher labeled probe by endonuclease 
could be detected by an increase of fluorescence, we then developed a FRET-based endonuclease inhibitory assay 
for screening small-molecule endonuclease inhibitors (Fig. 1b). In the assay, a DNA probe was designed to avoid 
the potential interferences of RNase contamination. Also, mock-purified pET-blank enzyme was included as a 
negative control to exclude potential E.coli-DNase influences. Even so, false positive results may be obtained in 
a FRET-based screening, typically due to compounds which are fluorescent quenchers or due to the inner filter 
effect42, i.e., the compound absorbs at either the excitation or emission wavelength. To address this weakness, an 
alternative gel-based endonuclease inhibitory test was conducted by making use of the hydrolysis property of PAN 
endonuclease (Fig. 2b). Apparently, our platform (Fig. 2a) enabled the initial identification of PAN endonuclease 
inhibitors and resulted in the discovery of novel antiviral compounds (Fig. 3a). Therefore, a high throughput 
screening based on this platform may be feasible when the production of PAN is scaled up.
ANA-0, the analog of PA-30, was highly effective in the treatment of influenza H1N1 virus (supplementary 
Fig. S2). Since the PAN domain is highly conserved among influenza A subtypes, it was inferred that ANA-0 
might be able to provide a broad-spectrum protection against infections by other subtypes of influenza A virus. 
Our results demonstrated that ANA-0 indeed impeded the replication of different subtypes of the virus, among 
which the H1N1 and H9N2 strains showed > 5 folds of sensitivity than that of the H3N2 and H7N9 strains 
(Fig. 4a). Alignment on the amino acid sequences by these 4 strains revealed one specific substitutions (V100A) 
within the PAN domain (supplementary Fig. S1). It was inferred that substitution V100A, when occurred in 
H3N2 and H7N9, might decrease the binding affinity of ANA-0 to PAN, thus the antiviral efficacies varied. In vivo 
study showed that ANA-0 protected mice against lethal challenge of influenza A H1N1 virus (Fig. 5a). Further 
Figure 5. In vivo antiviral activity of ANA-0 and PA-30. (a) Mice (10 per group) infected with LD80 (500 
PFU/mouse) of mouse-adapted A/HK/415742Md/09 H1N1 virus were treated with 2 mg/kg/day of ANA-0 
or PA-30 or zanamivir or PBS by intranasal administration. Treatments started at 6 h after virus challenge 
and continued for 6 doses in 3 days (2 doses/day). Difference between groups were compared and analyzed 
using Log-rank (Mantel-Cox) test. ***indicates p < 0.001 and **indicates p < 0.01 as compared to PBS-treated 
group. (b) Four mice from each group were euthanized at day 4 post-infection and lungs were collected for 
detection of viral loads by plaque assay (detection limit: 1:50) and RT-qPCR. The plaque was undetectable in 
the lung samples of zanamivir-treated mice. The results are presented as the mean values + SD. Differences 
between groups were compared and analyzed using a one-way ANOVA. ***indicates p < 0.001 and **indicates 
p < 0.01 as compared to PBS-treated group. (c) Histopathologic changes in mouse lung tissues collected at day 
4 post-infection. Representative histologic sections of the lung tissues from the mice were stained with H&E 
(magnification: × 100). Less inflammatory infiltrate and thickening of the alveolar septum (as alveolar damage) 
are shown in samples from mice treated with ANA-0, PA-30 and zanamivir as compared to that from PBS-
treated mice.
www.nature.com/scientificreports/
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comparison on the different time points of drug administration revealed that result of 3 or 6 h post-challenge 
showed better in vivo antiviral effect than that of 12 h (supplementary Fig. S3). In addition, there detected > 2 log 
reduction of viral load in the lungs of the ANA-0-treated mice when compared to that of the untreated control 
group (Fig. 5b). Inflammatory infiltrate and alveolar damage were also largely attenuated in the ANA-0 treated 
mice (Fig. 5c). These results suggest that ANA-0 has the potential to be developed as an effective anti-influenza 
therapeutic. Treatments through intranasal route deliver the drug into the influenza virus infection site directly. 
On the other hand, intranasal administration would significantly facilitate influenza virus infections and promote 
lung pathology43. Therefore, intranasal treatment of influenza virus infections requires several considerations, 
Figure 6. Antiviral mechanism of ANA-0. (a) Intracellular viral RNA (intra. vRNA) and supernatant viral 
RNA (sup. vRNA) were quantified in a time-of-addition assay. MDCK cells were inoculated with influenza 
H1N1 virus (MOI = 2), while ANA-0 (20 μM) or zanamivir (100 μM) was added at the time of virus absorption 
(− 1 h) and then removed or at 1 h post-infection (p.i.) and then maintained in the medium. vRNA copies in 
the cells or supernatants were determined at 6 h p.i. (b) MDCK cells were infected with influenza H1N1 virus 
with MOI of 2 for 1 h. The cells were washed and maintained in the medium containing ANA-0 (20 μM), 
or zanamivir (100 μM) or mock-treated (VC) thereafter. Intracellular virus-specific mRNA and vRNA were 
quantified at 3 or 6 h p.i. (c) Inhibitory effect of ANA-0 to viral polymerase activity was tested by a mini-
replicon assay. 293 T cells were transfected with plasmids encoding PB1, PB2, PA, NP genes, a firefly luciferase 
reporter-gene plasmid and an eGFP plasmid for transfection efficiency normalization. Indicated concentrations 
of ANA-0 were added at 5 h post-transfection. Luminescence and fluorescence were determined at 24 h post-
transfection, respectively. The experiments were carried out in triplicate and repeated twice. The results are 
presented as mean values ± SD. Differences between groups were compared and analyzed using a one-way 
ANOVA. **indicates P < 0.01 as compared with the mock-treated control.
Combination Ratio (IC50) IC50 Equivalenta
FICIbANA-0 : Zanamivir ANA-0 Zanamivir
10:1 0.25 0.03 0.28*
5:01 0.38 0.08 0.46*
1:01 0.12 0.12 0.24*
1:05 0.07 0.33 0.40*
1:10 0.04 0.35 0.39*
Table 1.  Antiviral results of combinational treatments. 1Concentration in IC50 equivalent was the 
normalized concentration that was calculated by dividing the IC50 of drug in combination with its IC50 
alone. 2FICI was the sum of ANA-0 and zanamivir IC50-equivalent concentrations used in each combination; 
3FICI < 0.5 was interpreted as significant synergistic effect.
www.nature.com/scientificreports/
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especially the virus challenge dose and the stress of repeated anesthesia to avoid compromising the effectiveness 
of a potential antiviral drug44,45. Taking account of the above factors, as well as the solubility limitation of ANA-0 
(i.e. 1 mg/ml in PBS), we chose the therapeutic regimen as described previously. During the submission of this 
manuscript, one study focusing on the structural and computational analyses of influenza endonuclease inhibi-
tors was published46, which might provide valuable information for the further optimization of ANA-0.
The ribonucleoprotein complexes (RNPs) of influenza virus are the independent functional units for viral 
mRNA transcription and vRNA replication10. The viral mRNA transcription is initiated by endonuclease cleavage 
of 5′ -capped RNA fragments from host pre-mRNAs, followed by the elongation and polyadenylation of polymer-
ase activity11. Subsequently, the vRNA replication proceeds, which requires the newly synthesized RNP compo-
nents that are the translation products of earlier step primary mRNA transcription47. Since ANA-0 targeted the 
Figure 7. Docking simulation of ANA-0 and PA-30 with influenza PAN domain. Two dimensional analysis (left) 
and ribbon diagram (right) of the interactions between ANA-0 (a) or its parental compound PA-30 (b) with PAN 
are shown. (a) ANA-0 is predicted to interact with the endonuclease pocket by contacting the catalytic residues 
Lys-134, the metal binding residues His-41, Glu-80, Asp-108, Glu-119 and two strictly conserved residues Arg-
84 and Lys-137. (b) PA-30 is predicted to interact with the residues Ala-20, Leu-42, Glu-80, Gly-81 and Leu-106. 
In 3D structural analyses, chemical structures of ANA-0 and PA-30 are shown as colored stick models, while 
interaction amino acid residues are labeled as grey. (c) Binding affinity (Kd) of ANA-0 and PA-30 to PAN protein 
were determined by isothermal titration calorimetry and compared with the reported value of DPBA.
www.nature.com/scientificreports/
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PA endonuclease domain, it was deduced that the compound should disrupt the virus life cycle by interfering 
with the initial transcription step. To demonstrate this hypothesis of antiviral mechanism, we first showed that 
ANA-0 could not inhibit virus entry (Fig. 6a). We then demonstrated that intracellular virus-specific mRNA was 
significantly suppressed at early stage of ANA-0 treatment, which might result in subsequent reduction of vRNA 
synthesis (Fig. 6b). The mini-replicon assay result further showed that the virus polymerase activity was impaired 
in the treatment of ANA-0 (Fig. 6c). The impeded vRNA synthesis may be due to that the progeny vRNPs are the 
pre-requisites of vRNA replication48. As the earlier phase of mRNA transcription impaired, the subsequent steps 
of protein synthesis and vRNA replication would be abrogated. These results have demonstrated that ANA-0 is an 
effective inhibitor of viral transcription.
The PAN domain harbors the endonuclease active cavity that is coordinated by the metal binding residues 
(His-41, Glu-80, Asp-108, and Glu-119), the putative catalytic residue Lys-134, and three strictly conserved 
residues (Arg-84, Tyr-130 and Lys-137)49. The molecular docking results predicted that ANA-0 engaged in the 
endonuclease active sites and interacted with most of these functional residues (Fig. 7a). In addition, ANA-0 and 
PA-30 bound tighter to the PAN than that of DPBA (Fig. 7c). This was in line with our primary screening result 
that ANA-0 and PA-30 exhibited lower IC50s in the FRET-based endonuclease inhibitory assay than that of DPBA. 
Therefore, our results suggest that ANA-0 may function as an optimal endonuclease inhibitor by interacting 
with the PAN metal binding residues and catalytic residues. Our work underscores the utility of suppressing PAN 
endonuclease activity as a promising anti-influenza strategy, similar design could be used to develop therapeutics 
that target to other functional domains of the viral polymerase, e.g. cap-binding domain of PB2 subunit50. Besides 
enzymatic activity, the correct assembly of subunits into functional RdRp is an essential step for influenza vRNA 
replication. Making use of this strategy, a group of PA C-terminal-targeted compounds were identified to disrupt 
PA-PB1 interaction with broad anti-Flu activity51. In the scenario of increasing drug resistance, combination 
study between PAN-targeted and PAC-targeted drugs could be carried out in the future.
Since the antiviral mechanism of ANA-0 was different from the commonly prescribed anti-influenza drug 
Relenza (zanamivir), we further investigated the antiviral efficacies of drug combinations and demonstrated the 
synergetic antiviral effect between these two compounds (Table 1). Obviously, therapeutics with synergistically 
active antiviral compounds provide several advantages over the single-agent treatment, such as enhanced anti-
viral potency, reduced drug dosage, delayed emergence of drug resistance and fewer side effect52,53. Importantly, 
in the circumstance that zanamivir is costly and the frequency of viral resistance to zanamivir is increasing glob-
ally7,54, ANA-0 provides a new addition to the arsenal of anti-influenza treatments.
The propensity of influenza virus to develop resistance to commonly used drugs requires continued develop-
ment of new therapeutics, especially those are not prone to escape mutation. In this study, we demonstrate the 
possibility of suppressing viral replication by abrogating the PA endonuclease activity. The established screening 
platform for endonuclease inhibitors provides new opportunities for the drug discovery. Importantly, the selected 
compound ANA-0 exhibits substantial potential for clinical applications.
Methods
Cells, viruses and chemical compounds. Madin-Darby canine kidney (MDCK) cells were main-
tained in minimum essential medium (MEM) supplemented with 10% heat-inactivated Fetal Bovine Serum 
(FBS), 50 units/ml penicillin and 50 μg/ml streptomycin. Upon virus infection, the infected cells were main-
tained in FBS free media supplemented with 1 μg/ml TPCK trypsin. A total of 8 strains/6 subtypes of influenza 
A virus, A/HK/415742/09(H1N1), A/Hong Kong/1/1968 (H3N2), A/Shenzhen/406 H/2006(H5N1), A/Hong 
Kong/156/97(H5N1), A/Vietnam/1194/2004(H5N1), A/Netherlands/219/2003(H7N7), A/Anhui/1/2013(H7N9), 
and A/HK/1073/1999 (H9N2), were cultured in MDCK cells. A mouse-adapted strain, A/HK/415742Md/09 
(H1N1), was propagated in chick embryo. The cultured viruses were titrated by plaque assay and stored at − 80 °C 
in aliquot. All the viruses were conserved by the P3 laboratory, University Pathology Building of Queen Mary 
Hospital, the University of Hong Kong. All experiments with live viruses were conducted using biosafety level 2 or 
3 facilities as described previously55. All the testing compounds were purchased from ChemBridge Corporation 
unless specified.
Expression and purification of the PAN. The PAN domain was expressed in Escherichia coli (E. coli) and 
purified by His tag affinity chromatography as described previously56. A blank pET32a (+ ) vector (pET-blank) 
was transformed, expressed, purified and used as a mock-purified enzyme control.
FRET-based endonuclease inhibitory assay. To detect the endonuclease activity of the 
PAN, FRET-based endonuclease assay was performed in 96-well black microplates using the method 
described previously with modifications18,29. Briefly, a dual-labeled single-strand DNA oligonucleotide 
(FAM-TCTCTAGCAGTGGCGCC-TAMRA) was synthesized as a detection probe, with FAM (fluorophore) and 
TAMRA (quencher) conjugated to its 5′ and 3′ terminals, respectively. In a volume of 100 μl, PAN of various con-
centrations (75, 50, and 25 ng/μl) were incubated with 200 nM DNA probe. Fluorescence signals due to the endo-
nuclease cleavage were measured using VICTOR™ X3 multilabel plate reader (Perkin Elmer) at the wavelength 
of 485 nm excitation and 535 nm emission. pET-blank protein (75 and 50 ng/μl) and ‘substrate only’ were also 
included as a mock enzyme control and a background control, respectively. The reaction buffer contained 50 mM 
HEPES (pH 7.8), 150 mM NaCl and 1 mM MnCl2. To validate the specificity, FRET-based endonuclease inhibitory 
assay was performed. A known inhibitor of influenza endonuclease activity, namely 2, 4-dioxo-4-phenylbutanoic 
acid (DPBA), was used as a positive control36. DPBA was dissolved in DMSO and serially diluted to 100, 25, 6.25, 
1.56 μM and incubated with the mixture of PAN (75 ng/μl) and probe (200 nM).
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Gel-based endonuclease inhibitory assay. Alternatively, the endonuclease inhibitory activity of individ-
ual compound could be detected by a DNA-gel based assay56, in which a single-stranded circular DNA M13mp18 
(NEB) was used as the substrate. In a 10 μl reaction volume, 10 μM of each compound was incubated with the 
mixture of 1 μM of PAN enzyme and 0.2 μg substrate at 37 °C. After 3 h, the reaction was quenched by addition of 
20 mM EGTA (Sigma) and final products were loaded for DNA agarose gel electrophoresis and visualized after 
ethidium bromide staining.
Small-molecule compounds screening. First, a primary screening of the 950 small-molecule com-
pounds was conducted using the same conditions as described in the FRET-based endonuclease inhibitory 
assay, in which each compound was tested at the concentration of 10 μg/ml. The positive compounds selected 
by FRET-based endonuclease inhibitory assay were then verified by gel-based endonuclease inhibitory assay. A 
dose–response analysis of PAN endonuclease inhibition was then done utilizing both assays. Next, a secondary 
screening using plaque reduction assay was performed to evaluate the in vitro anti-H1N1 efficacies of the identi-
fied compounds, in which selected compounds were serial-diluted (10, 5, 2.5, 1.25, and 0.625 μM) and tested. The 
compounds that showed dose-dependent plaque reductions were selected for further study.
Selectivity index. Selectivity index (SI) of each compound was defined as the ratio of CC50 over IC50. CC50 
value was determined with MTT assay according to the manufacturer’s protocol (Invitrogen), while IC50 data 
was obtained by plaque reduction assay. Both assays were done in MDCK cells and values were calculated using 
Sigma plot 12.0 (SPSS).
The evaluation of cross-protection. The antiviral effect of compound ANA-0 and PA-30 were tested 
against multiple subtypes of influenza virus, including H1N1, H3N2, H5N1, H7N7, H7N9, and H9N2. Briefly, 
MDCK cells were infected with the viruses at multiplicity of infection (MOI) of 0.002. One hour after virus inocu-
lation, the inoculum was removed and replaced by fresh MEM medium containing 1 μg/ml TPCK trypsin (except 
H5N1) and serial-diluted compound. The cell-free supernatants were collected at 24 h post-infection and applied 
to virus titration by plaque assays.
Assessment of combination treatment in vitro. The potential synergistic antiviral effect of ANA-0 and 
zanamivir (MedChem) was evaluated in cell cultures as described previously39. In brief, MDCK cells in 96-well 
plates were infected with the viruses at low MOI (0.002) for 1 h, washed and then cultured with MEM medium 
containing zanamivir or ANA-0, alone or in combinations. After 24 h incubation at 37 °C, supernatants of var-
ious treatments were collected for virus titration. Five combinations of ANA-0 and zanamivir, at the fixed IC50 
ratios of 10:1, 5:1, 1:1, 1:5 and 1:10, were included. In each combination, six 2-fold serial dilutions of the stock 
solution were tested to plot the dose inhibition curve, based on which IC50 of individual ANA-0 or zanamivir was 
determined. Subsequently, fractional inhibitory concentration index (FICI) was calculated using the following 
formula: FICI = [(IC50 of ANA-0 in combination)/(IC50 of ANA-0 alone)] + [(IC50 of zanamivir in combination)/
(IC50 of zanamivir alone)]. FICI < 0.5 was interpreted as a significant synergistic antiviral effect57.
In vivo evaluation of antiviral effect. BALB/c female mice, 6–8 weeks old, were kept in biosafety level-2 
housing and given access to standard pellet feed and water ad libitum. All experimental protocols followed the 
standard operating procedures of the approved biosafety level-2 animal facilities and were approved by the 
Animal Ethics Committee in the University of Hong Kong. All experiments were performed in accordance with 
the approved guidelines. After anesthesia, a total of 56 mice in four groups (14 mice/group) were inoculated 
with LD80 (80% lethal dose, 500 PFU/mouse) of mouse-adapted influenza H1N1 virus A/HK/415742Md/09. 
The therapeutic treatment initiated 6 h post-virus-challenge by intranasal route. Briefly, the mice were anesthe-
tized by intraperitoneal injection of ketamine-xylazine (50/5 mg/kg). Two groups of the mice were treated with 
ANA-0 and PA-30, respectively. The third group of mice was inoculated with zanamivir as a positive control. The 
last group was administrated with PBS as an untreated control. Two doses per day of 20 μl of 1 mg/ml of ANA-0 
or PA-30 or zanamivir or PBS, i.e. 2 mg/kg/day of each agent were intranasally administered for 3 days. Animal 
survival and body weight were monitored for 21 days after virus inoculation. A body weight loss of 25% was set as 
the humane endpoint58. Four mice in each group were euthanized randomly on day 4 post-challenge and mouse 
lungs were collected. Half of lung tissues were frozen for virus titration by standard plaque assay, while half lungs 
were immediately fixed in 10% buffered formalin for histopathologic analyses as described previously55.
The investigation of antiviral mechanism. MDCK cells were inoculated with influenza H1N1 virus 
at MOI of 2. To investigate which stage of virus life cycle was interfered by the compound, ANA-0 (20 μM) was 
added during the time of virus absorption (− 1 h) or at 1 h post-infection. For the former, infectious inoculum 
containing the tested compound was replaced with fresh medium after 1 h incubation; for the later, the compound 
was maintained in the fresh medium after virus entry. Virus yield in the cells or supernatants was determined 
at 6 h p.i. by RT-qPCR. To determine the virus replication and transcription upon compound treatment, intra-
cellular viral mRNA and vRNA were detected. After the virus absorption, the inoculum was removed and cells 
were maintained in the presence or absence of ANA-0 (20 μM). At 3 and 6 h post-infection, cell lysates were 
collected for RT-qPCR analyses. To obtain the complementary DNA (cDNA) that derived from intracellular 
viral mRNA or vRNA templates, total RNAs were first extracted from the cell lysates using the RNeasy mini kit 
(QIAGEN), then reverse transcribed with the first strand cDNA synthesis kit (Roche) using anchored-oligo(dT)18 
primer (for mRNA) or Uni-12 primer59 (for vRNA), respectively. The transcribed cDNA levels were determined 
by RT-qPCR with specific primers of the HA gene. In the experiments, zanamivir (100 μM) was included as 
a control of virus release inhibitor. The inhibitory effect of compounds on polymerase activity was evaluated 
using a mini-replicon assay as described60. Briefly, 293 T cells were transfected with 50 ng of each pHW2K-PB1, 
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pHW2K-PB2, pHW2K-PA, pHW2K-NP, pIRES-eGFP (Clontech) and 100 ng of firefly luciferase reporter plas-
mid pPolI-fluc using Lipofectamine 3000 (Invitrogen). Five hours post-transfection, the medium was replaced 
by DMEM with 0.5% FBS containing various concentrations (50, 25, 12.5, 6.25, 3.125 and 0 μM) of ANA-0. At 
24 h post-transfection, cells were lysed, first applied to measure eGFP fluorescence for transfection efficiency 
normalization and then applied to luminescence assay using the luciferase reporter assay system (Promega). Both 
fluorescence and luminescence intensities were measured in a Victor X3 Multilabel plate reader (Perkin Elmer).
Molecular docking. The structure of PAN bound with DPBA was retrieved from RCSB protein data bank 
(PDB: 4E5G)17. The co-crystallized compound was removed from the structure using PDB editior. Docking 
analysis was performed with molecular opreting enviornment (MOE) softwere (Chemical Computing Group, 
Quebec, Canada), considering the protein as a rigid body while ligands were fully flexible. One hundred docking 
solutions were computed for the ligand-protein interaction and all other parameters were set to default. The 
best docking score and configuration was selected for further analysis and visualized by Schrodinger maestro 
(Schrödinger, New York, USA).
Isothermal Titration Calorimetry. Isothermal titration calorimetry (ITC) titrations were performed with 
an Auto-iTC200 Isothermal Titration Calorimeter (MicroCal) according to the protocol described by DuBois 
et al.17. Data were analyzed using MicroCal Origin 7.0 software using a one-site binding model.
Statistical analysis. The data were evaluated for statistical significance using one-way ANOVA or Log-rank 
(Mantel-Cox) test as indicated in the figure legends (Prism 6.0, GraphPad, Inc). Values of p < 0.05 were consid-
ered to represent a statistically significant difference.
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